Acurx Pharmaceuticals
Phase 1New England Journal of Medicine , “One Pivotal Trial, the New Default Option for FDA Approval – Ending the Two-Trial Dogma,” by Vinay Prasad, M.D., M.P.H.1 and Martin A. Makary, M.D., M.P.H.1
Founded
2017
Focus
Small Molecules
About
New England Journal of Medicine , “One Pivotal Trial, the New Default Option for FDA Approval – Ending the Two-Trial Dogma,” by Vinay Prasad, M.D., M.P.H.1 and Martin A. Makary, M.D., M.P.H.1
Funding History
3Total raised: $25.5M
IPO$15MIPOFeb 11, 2021
Series A$8.5MUndisclosedMay 15, 2019
Seed$2MUndisclosedJun 15, 2017
Company Info
TypePrivate
Founded2017
LocationStaten Island, United States
StagePhase 1
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile